title: FDA allows controversial bowel drug back on to market.
authors.forename: Michael
authors.initials: M
authors.lastname: McCarthy
mesh_terms: D002243:Carbolines / Q000009:adverse effects*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012702:Serotonin Antagonists / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron